Morepen Laboratories Limited (MOREPENLAB) Price & Analysis

Compare

13 Followers

MOREPENLAB Stock Chart & Stats

₹41.99

-₹1.18(-1.56%)

At close: Jan 08 4:00 PM EST

₹41.99

-₹1.18(-1.56%)

Day’s Range― - ―

52-Week Range₹33.47 - ₹70.40

Previous CloseN/A

Volume3.34M

Average Volume (3M)88.30K

Market Cap

₹21.24B

Enterprise Value₹22.75B

Total Cash (Recent Filing)₹1.27B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)21.4

Beta2.02

Next Earnings

May 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.49%

Share Statistics

EPS (TTM)0.50

Shares Outstanding547,953,700

10 Day Avg. Volume126,704

30 Day Avg. Volume88,304

Financial Highlights & Ratios

PEG Ratio1.32

Price to Book (P/B)2.29

Price to Sales (P/S)1.45

P/FCF Ratio-28.80

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage / Strong Balance SheetA debt-to-equity ratio of 0.09 and 65% equity ratio signal a conservatively financed balance sheet. This durable financial strength provides flexibility to fund capex, R&D or acquisitions without high interest burden, and improves resilience to industry cyclicality.

Consistent Revenue Growth & Healthy Gross MarginSustained top-line growth combined with a strong gross margin (34.4%) indicates the company retains pricing and cost advantages in production. This durable margin buffer supports reinvestment, covers operating leverage, and underpins longer-term EBITDA generation.

Diversified Pharma Model: APIs And FormulationsOperating across APIs and finished formulations creates diversified revenue streams and multiple routes to market (branded, contract, exports). Manufacturing scale and product mix reduce reliance on a single segment, supporting steadier revenues and commercial resilience.

Bears Say

Negative Free Cash FlowDespite higher operating cash flow, negative free cash flow in 2025 means cash available after capex is constrained. Persistently negative FCF limits ability to self-fund growth, dividends or debt reduction and may force external financing or cutbacks in investment.

Compression In Net Profit MarginsA drop to a 6.5% net margin, despite solid gross margins, suggests rising SG&A, R&D, or other operating pressures. If persistent, margin compression will reduce retained earnings and ROE, constraining long-term reinvestment and shareholder returns.

Declining EPS GrowthA steep year-over-year EPS decline (~24%) signals earnings volatility or one-off impacts and weakens the company’s ability to compound shareholder value. Continued EPS contraction would hinder capital allocation, reduce buffer for downturns, and impair long-term strategic initiatives.

Morepen Laboratories Limited News

Morepen Labs Reports Minimal Activity in SEBI Special Window for Physical Share Transfers

Morepen Laboratories Limited ( ($IN:MOREPENLAB) ) just unveiled an announcement. Morepen Laboratories has reported to the stock exchanges...

25d ago

Morepen Laboratories Reports No Share Transfer Activity in November 2025

Morepen Laboratories Limited ( ($IN:MOREPENLAB) ) has issued an update. Morepen Laboratories Limited reported to the stock exchanges...

3M ago

Morepen Laboratories Releases Financial Results for September 2025

Morepen Laboratories Limited ( ($IN:MOREPENLAB) ) just unveiled an announcement. Morepen Laboratories Limited has announced the publication of...

3M ago

Morepen Laboratories Subsidiary Forms Joint Venture in Medical Devices

Morepen Laboratories Limited ( ($IN:MOREPENLAB) ) has issued an announcement. Morepen Laboratories Limited announced that its subsidiary, Morepen...

6M ago

MOREPENLAB FAQ

What was Morepen Laboratories Limited’s price range in the past 12 months?

Morepen Laboratories Limited lowest stock price was ₹33.47 and its highest was ₹70.40 in the past 12 months.

What is Morepen Laboratories Limited’s market cap?

Morepen Laboratories Limited’s market cap is ₹21.24B.

When is Morepen Laboratories Limited’s upcoming earnings report date?

Morepen Laboratories Limited’s upcoming earnings report date is May 06, 2026 which is in 73 days.

How were Morepen Laboratories Limited’s earnings last quarter?

Morepen Laboratories Limited released its earnings results on Feb 10, 2026. The company reported ₹0.502 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.502.

Is Morepen Laboratories Limited overvalued?

According to Wall Street analysts Morepen Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Morepen Laboratories Limited pay dividends?

Morepen Laboratories Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.49%. See more information on Morepen Laboratories Limited dividends here

What is Morepen Laboratories Limited’s EPS estimate?

Morepen Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Morepen Laboratories Limited have?

Morepen Laboratories Limited has 547,953,700 shares outstanding.

What happened to Morepen Laboratories Limited’s price movement after its last earnings report?

Morepen Laboratories Limited reported an EPS of ₹0.502 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.24%.

Which hedge fund is a major shareholder of Morepen Laboratories Limited?

Currently, no hedge funds are holding shares in IN:MOREPENLAB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Morepen Laboratories Limited

Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, anti-hypercholesterolemic, anti-hypertensive, and anti-diabetic drugs; point of care and medical devices; and home diagnostic products, such as air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, strips, sanitizers, disinfectant solutions, masks and gloves, and others. It also provides Burnol, a burn cream; Lemolate for cough and cold; and Fiber-X, a sat isabgol; and formulations for gastro, antibiotics, vitamins, nutritional, and anti-diabetics, as well as cardiac. In addition, the company is involved in the product contract manufacturing and brand sharing businesses; and provision of over-the-counter products under the Dr. Morepen brand. It exports its products to approximately 75 countries. Morepen Laboratories Limited was incorporated in 1984 and is based in New Delhi, India.